We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The Savanna automated sample-to-result multiplex RT-PCR testing platform (Photo courtesy of QuidelOrtho)
Image: The Savanna automated sample-to-result multiplex RT-PCR testing platform (Photo courtesy of QuidelOrtho)

QuidelOrtho Corporation (San Diego, CA, USA) is highlighting the latest advances in laboratory testing and point-of-care diagnostics at the Euromedlab Congress in Rome. The company is demonstrating how effectively combining point-of-care and laboratory testing can enhance patient care and improve overall healthcare outcomes. QuidelOrtho’s advanced lab management tools and expertise can help labs streamline their workflow, automate operations, and efficiently analyze data, thereby enhancing overall efficiency without compromising on quality.

At EuroMedLab Rome 2023, the company is demonstrating Savanna – a true sample-to-result point-of-care multiplex molecular solution. The cutting-edge system can accurately and simultaneously test for SARS-CoV-2, Flu A, Flu B, and RSV on a panel within 20 minutes. Besides delivering rapid results, the RVP4 also delivers superior clinical performance and possesses the capability to detect SARS-CoV-2 variants. Additionally, QuidelOrtho is demonstrating how its Vitros XT 7600 Integrated System can boost lab efficiency, offering a wide-ranging menu of over 160 assays, thus future-proofing labs and preparing them for potential Vitros Automation incorporation. This system is also time-efficient, with a first-pass yield of 96.5% and incorporates E-Connectivity Technology for uninterrupted operation. The company's innovative waterless system further maximizes lab space and enhances productivity.

Among QuidelOrtho’s innovative point-of-care solutions being featured at the industry event is the TriageTrue High Sensitivity Troponin I Test. This revolutionary test empowers medical professionals to make informed decisions that lead to better patient outcomes and overall improved healthcare efficiency. The test merges ER and lab testing, delivering high diagnostic precision with results available in under 20 minutes. The quick results can expedite patient handling, minimize hospital stay duration, and enhance ED throughput. In addition, QuidelOrtho is participating in the Euromedlab 2023 Satellite Meeting - Point-of-Care Testing: Home, Hospital and Beyond event. The company’s Vendor Talk by Dr. Holger Gundelach, Head of EMEA POC-IA Business Unit and Clinical Value at QuidelOrtho, on "The time is now – Accelerate patient management at the point-of-care" will be providing valuable insights and exploring the future of point-of-care testing.

Related Links:
QuidelOrtho Corporation 

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Malaria Rapid Test
ASSURE Malaria P.f/P.v Rapid Test
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.